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Abstract: This is a report of a cluster randomized clinical trial evaluating the effectiveness of a
church-based educational intervention aimed at improving African Americans’ (AA) participation
in clinical trials. Two hundred and twenty-one AA subjects ages ě50 years from six predominantly
AA churches were randomized to intervention or control condition. The intervention included
three educational sessions about clinical trials and health disparities; control participants completed
questionnaires. Primary endpoints of the study were differences in individual subjects' intentions
to obtain clinical trial information and intention to join a clinical trial, as determined by 10 point
scale items at baseline, three and six months. A statistically significant increase in the intention
to obtain clinical trial information at the three and six month time points was observed in the
intervention group, but not the control group. Older participants (65–95 years) were less likely
than younger participants (50–64 years) to increase their motivation to seek clinical trial information
by the three and six month time points. No significant increases were observed in intention to join
clinical trials. This randomized trial shows that AA church-based educational interventions are
likely to increase the motivation of AA subjects to obtain clinical trial information and are therefore
potentially effective at ameliorating the underrepresentation of AA subjects in clinical trials.
Keywords: health disparities; clinical trials; churches; study recruitment; African Americans

1. Introduction
Despite decades of significant medical advances that have resulted in approval of novel
prevention strategies, therapeutics, and medical devices, clinical trials continue to be challenged
by underrepresentation of racial and ethnic minority participants [1,2]. Recent data demonstrate
that overall participation rates among racial/ethnic minorities continue to lag behind those of other
groups for various types of clinical trials [1,3,4]. Moreover, enrollment rates are lower among the
elderly (typically defined as those ě70 years) when compared to younger participants [5–7], and
lower among women than men in cardiology trials [1,4]. Older minority populations (age ě65 years)
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carry a heavy burden of chronic and infectious disease morbidity and mortality, and are likely
to be prime beneficiaries of medical advances if clinical trial results yield generalizable findings
for this group [6,8]. Thus, underrepresentation of this group in trials presents a significant issue
given the dramatic increases in the aging population that is also a growing consumer segment for
pharmaceuticals and medical products [9,10].
With an increasing aging minority population, it is critically important that randomized
clinical trials include adequate representation of this segment of the population [6,11]. Thus,
underrepresentation has become an issue of social justice due to the potential for realization of
significant health inequities in the years ahead [12,13]. Although older persons (ages ě65 years)
comprise 14% of the developed world’s population, this group also consumes one-third of
pharmaceutical products, most of which were tested with non-representative populations [14].
Enrollment of persons ě65 years, including racial and ethnic minorities, in clinical trials is therefore
of global interest to address health disparities and the achievement of Healthy People 2020
objectives [15,16]. For this reason, the Food and Drug Administration (FDA), the U.S. Centers for
Disease Control and Prevention (CDC), and other groups are now strongly advocating for reduction
in age-based exclusions when feasible in clinical trials [16,17].
Significant challenges have been previously described in the recruitment of minorities including
older adults (50–69 years) and elderly populations (ě70 years) [10,18,19]. These include logistical
challenges such as getting to clinical locations, a lack of social support and social norms promoting
participation, experiences of perceived stigma in medical environments, researcher distrust, health
challenges, and adequate compensation [20–24]. Among those who have examined factors associated
with clinical trial participation, perceived health status and personal/social benefit associated with
enrollment factored as strong behavioral predictors [25]. In addition, simply knowing about studies
recruiting the population has facilitated involvement of older adults, especially if communication
was with a family member or health navigator [26]. Thus, awareness of trials open to enrollment and
the personal relevance of the health topics addressed by available clinical studies, combined with
perceived social support, have been demonstrated as important facilitators for engagement of this
population [26].
Other studies have also highlighted the role of African American churches in recruitment of
Southern African Americans, as this influence extends beyond religion [27,28]. For many older
African Americans, the church is the centerpiece of religious, social, and political life. Additionally,
the church provides an effective means to involve Southern African Americans in clinical research,
especially women who belong to communities of faith, as they have been shown to be receptive
to health messages delivered in this setting [29,30]. With the support and involvement of pastors,
community members, and subject matter experts, we developed and tested an intervention entitled
“Delivering a Dose of Hope” to address the problem of clinical trial underrepresentation among a
specific segment of African Americans [29].
2. Experimental Section
2.1. Design
This study employed a cluster randomized study design to evaluate an educational intervention
developed to increase clinical trial participation among African Americans aged 50 years and
older [29]. Twenty churches in the Atlanta metropolitan area with ě30% membership of African
American congregants aged 50 and older were identified through ethnographic observation and
informant interviews. The identified churches were enumerated based on denomination and
estimated congregational membership to allow for matched pair selection. Three pairs of churches
were then randomly selected to participate. One church in each pair was assigned to the control
group while its match received the intervention.
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Following church selection, study participants for each arm were recruited from their respective
churches. Within churches, recruitment occurred through flyers, outreach, and health minister or
pastor referral to the program staff for eligibility screening. To be considered for inclusion in the
trial, an individual had to be ě50 years, identify as Black/African American, and may not have
previously participated in any clinical trials. Based on these criteria, we obtained written consent
from 221 persons who were eligible to participate.
2.2. Participants
A total of 221 subjects between the ages of 50 and 95 were recruited from the six churches. Of
these, 109 participants were in the control group and 112 participants were in the intervention group.
2.3. Intervention
Members of the intervention group participated in three information sessions about clinical trials
and related health issues guided by church leaders, subject matter experts, and clinical researchers.
The church leaders included health ministers with medical degrees and/or doctorates. We also
invited Center Disease Control (CDC) public health practitioners with doctorates to speak. They
developed PowerPoint presentations and handouts, and created interactive group exercises. Our
clinicians and public health experts included faculty and staff from the Emory School of Medicine
and Rollins School of Public Health and the Grady Healthcare System who held medical (MD) and
public health (PhD and MPH) degrees. Special care was taken to recruit racially and ethnically
diverse “program faculty” from within and outside the churches to develop and present the material
in the designated three-hour time frame per session. Each presentation lasted up to 40 min with
approximately 20 min of dedicated group discussion time for that topic with the speaker/subject
matter expert program faculty. The sessions included discussions on lack of community participation
in clinical trials (and related historical abuses), concerns about participant safety, clinical trial ethics,
the influence of social networks, and health concerns relevant to the participants for which clinical
trials were available for enrollment [29].
Control group participants completed questionnaires. They did not engage in any information
sessions regarding enrollment in clinical trials, but were invited to attend community events such
as health fairs and screenings, and educational presentations on health topics unrelated to clinical
trials (e.g., mammography screening). Participants in both groups were notified of studies currently
recruiting in the community through monthly telephone and email outreach.
2.4. Survey Measures
All study participants also completed questionnaires on attitudes, beliefs, and perceptions
towards clinical research upon enrollment, and at three and six months after enrollment. The
questionnaires consisted of items related to demographics, relationships with healthcare providers,
attitudes about influenza and immunization, social ties and channels of communication, and
attitudes, beliefs, and perceptions towards clinical research and participation in clinical trials. Study
participants’ clinical trial enrollment was followed for an additional 18-month period after the
six-month questionnaire.
As the primary endpoints, this interim analysis focused on the effect of the intervention on
participants’ self-reported intentions to contact Emory University’s clinical study sites for information
about clinical trials and intentions to join clinical trials. Final trial enrollment outcomes, and the effects
of attitudes, beliefs, and social networks will be assessed in future studies. The primary hypothesis
for this interim analysis was that the intervention would lead to increases in participants’ intentions
to seek information about and join clinical trials. In future analyses, we will examine how these
intentions translate into action.
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2.5. Measures of Intention to Participate in Clinical Trials
We examined the intervention’s effects on two trial participation intention measures:
(1) participants’ self-reported intention to seek information about clinical trials and (2) their intention
to participate in clinical trials. Intention to participate in clinical trials was measured through two
survey items: (1) intention to contact Emory University about participation in clinical trials and
(2) intention to join a clinical trial, each measured at baseline, three months, and six months. Intention
to seek information was measured by the question “On a scale from 1 (definitely not) to 10 (definitely
so), rank your likelihood of contacting Emory University about being in a medical research study in the
next 6 months,” where participants circled the appropriate number. Intention to join was measured
with the question, “On a scale from 1 (definitely not) to 10 (definitely so), rank your likelihood of
joining a medical research study within the next 6 months.” On the three- and six-month surveys,
participants were asked whether they had sought information about clinical trials or joined a clinical
trial since the previous survey. Those who reported seeking information about clinical trials were not
asked their intentions to seek information, and were instead assigned a likelihood of 10 for intention
to seek information for the appropriate time point. Similarly, those who reported that they had
enrolled in a clinical trial at three or six months were assigned a likelihood of 10 for intention to
join a clinical trial.
2.6. Statistical Analysis
Statistical analyses were performed using SPSS version 22.0 for Windows (IBM SPSS Inc.,
Chicago, IL, USA). Descriptive statistics were calculated for all variables, including means and
standard deviations for continuous variables and frequencies and percentages for categorical
variables. Chi-square and Mann-Whitney U-tests of independence were used to assess significant differences
in sociodemographic variables between the control and intervention groups. Multivariable linear
mixed effects models were used to examine the influence of the intervention on self-reported
intention to seek information about and intention to join clinical trials while adjusting for several
covariates, including age, gender, income, and baseline intentions. A single model was fitted to
each outcome at each of the three-month and six-month time points, and included a random effect
to account for the correlation between individuals within the same churches due to the cluster
sampling methodology. Potential interactions between assigned groups and each of the covariates
were examined, and significant interactions were included in the final model. Participants with
missing outcomes or covariates were accounted for using casewise deletion.
Within the control and intervention groups, additional mixed effects models were used to
examine changes in mean intention to seek information about or join clinical trials. These models
adjusted for baseline intentions, age, and interaction between baseline intentions and intervention.
Estimated marginal mean change in intention was calculated for each group and evaluated for
significance using t-tests. All statistical tests were two-tailed and evaluated at a significance level
of 0.05. Confidence intervals were calculated at a 95% significance level.
3. Results
3.1. Sample Characteristics
A total of 221 subjects participated in the study, 112 in the intervention group and 109 in the
control group. The mean age was 64.0 (SD = 7.7) and 78.7% (n = 174) of the participants were
female (Table 1). Most participants had at least completed high school (94.1%, n = 208), with 64.2%
(n = 142) having completed some form of post-secondary education. The majority of participants
(66.1%, n = 146) had a household income of less than $60,000. Slightly less than half of all participants
were married (46.2%, n = 102) and another 26.7% (n = 59) were divorced/separated. There were
no significant differences in gender, education, or income between the control and intervention
groups (Table 2). However, there was a statistically significant difference in the age distribution
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(Mann-Whitney U-Test; p = 0.03), with the control group having a significantly higher proportion
of 70–79 year olds than the intervention group (z-test, p < 0.05).
Table 1. Sample characteristics.
Characteristics

n

%

Total
Gender
Male
Female
Age (Mean = 64, Median = 64, Standard Deviation = 7.7)
50–59
60–69
70–79
80–89
90–99
Missing
Education
Grade K–8
Grade 9–11
High School/GED
Technical/Vocations/Associates
Bachelor’s Degree
Master’s Degree
Doctorate
Income
<$20,000
$20,001–$40,000
$40,0001–$60,000
$60,001–$80,000
$80,001–$100,000
>$100,000
Missing
Relationship Status
Single/Never Married
Married/Domestic Partner
Divorced/Separated
Widowed
Other
Assigned Group
Intervention
Control

221

100

47
174

21.3
78.7

62
108
41
5
2
3

28.1
48.9
18.6
2.3
0.9
1.4

3
10
66
66
37
33
6

1.4
4.5
29.9
29.9
16.7
14.9
2.7

61
49
36
20
19
13
23

27.6
22.2
16.3
9.0
8.6
5.9
10.4

24
102
59
35
1

10.9
46.2
26.7
15.8
0.5

112
109

50.7
49.3

Table 2. Participant characteristics by assigned group.
Characteristics
Total
Gender
Male
Female
Age
50–59
60–69
70–79
80–89
90–99
Missing

Control

Intervention
N
%a

N

%a

109

49.3

112

50.7

22
87

20.2
79.8

25
87

22.3
77.7

25
53
29
1
0
1

23.1
49.1
26.9
0.9
0
–

37
55
12
4
2
2

33.6
50.0
10.9
3.6
1.8
–

p–Value b
0.41

0.03
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Table 2. Cont.
Characteristics
Education
Grade K–8
Grade 9–11
High School/GED
Technical/Vocations/Associates
Bachelor’s Degree
Master’s Degree
Doctorate
Income
<$20,000
$20,001–$40,000
$40,0001–$60,000
$60,001–$80,000
$80,001–$100,000
>$100,000
Missing
Relationship Status
Single/Never Married
Married/Domestic Partner
Divorced/Separated
Widowed
Other
a

N

Control
%a

Intervention
N
%a

1
3
33
31
23
14
4

0.9
2.8
30.3
28.4
21.1
12.8
3.7

2
7
33
35
14
19
2

1.8
6.3
29.5
31.3
12.5
17.0
1.8

32
27
16
8
6
7
13

33.3
28.1
16.7
8.3
6.3
7.3
–

29
22
20
12
13
6
10

28.4
21.6
19.6
11.8
12.7
5.9
–

10
47
36
16
0

9.2
43.1
33.0
14.7
0

14
55
23
19
1

12.5
49.1
20.5
17.0
0.9

p–Value b
0.45

0.50

0.25

Percentage of non-missing responses within study group.

Int. J.allEnviron.
Res. Public Health 2015, 12
other variables.

b

Mann-Whitney U-test for age; chi-square test for

8

(SD
= 3.3, missing
= 4), while
the mean
3.2.
Intention
to Participate
in Clinical
Trialsscore for the intervention group was 7.5 out of 10 (SD = 3.1,
missing = 10). At six months, the control group had a mean score of 6.5 out of 10 (SD = 3.6, missing = 5)
Changes over time in both mean intention to seek information about, and intention to join clinical
and for
the each
intervention
group
a mean
score of
out of intentions
10 (SD = 3.1,
missing
= 9).
trials
group are
shown
in Figure
1. 7.1
Baseline
to seek
information
about clinical trials
Intention
to
join
clinical
trials
at
baseline
was
similar
for
the
two
groups
as
well,
with
control
were similar for the two groups (Figure 1a), with a mean baseline score of 5.5 out
of the
10 (SD
= 2.9,
group
having
a
mean
baseline
score
of
5.8
out
of
10
(SD
=
2.7,
missing
=
4)
and
the
intervention
missing = 2) for the control group, and 5.7 out of 10 (SD = 2.9, missing = 3) for the interventiongroup
group.
scoremonths,
of 5.8 out
10 (SD
= 2.7, to
missing
= 3) (Figurescore
1b). for
At 3the
months,
meanwas
score
Ata three
theofmean
intention
seek information
controlthe
group
6.6 for
outthe
of 10
control
group
was
5.9
out
of
10
(SD
=
2.7,
missing
=
4)
and
for
the
intervention
group
6.2
out
of
10
(SD = 3.3, missing = 4), while the mean score for the intervention group was 7.5 out of 10 (SD = 3.1,
missing
= 10).
At six=months,
the control
group
had
of 6.5
of 10
(SD
= 3.6,
missing
= 5)
(SD = 2.8,
missing
9). The mean
intention
score
at 6a mean
monthsscore
was 5.7
outout
of 10
(SD
= 3.0,
missing
= 5)
and
the
intervention
group
a
mean
score
of
7.1
out
of
10
(SD
=
3.1,
missing
=
9).
for the control group and 6.3 out of 10 (SD = 2.9, missing = 9) for the intervention group.

(a)

(b)

Figure
1. (a)
in mean
intention
to seek
over time;
change
mean in
intention
Figure
1.Change
(a) Change
in mean
intention
toinformation
seek information
over(b)
time;
(b) in
change
mean to
joinintention
over time.
to join over time.

Results from the multivariable linear mixed models for three- and six-month intentions to seek
information about and join clinical trials are shown in Table 3. Participation in the intervention group
was not associated with greater improvement in intention to seek information about or join clinical trials
at follow-up. Age was significantly related to three-month intention to seek information (p < 0.05),
six-month intention to seek information (p < 0.01), three-month intention to join (p < 0.01), and
six-month intention to join (p < 0.05), with older participants indicating less increase, or greater
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Table 3. Intervention effect estimates and results from multivariable linear mixed models.
Predictor Variable

Intervention (ref = control)
Baseline Intention
Age
Gender (ref = male)
Income
Intervention ˆ Baseline e
Intervention ˆ Age f

Intention to Join

Intention to Seek Information
3 Months (miss = 42)

6 Months (miss = 43)

β (95% CI)

p´value

0.4 (´2.27, 3.08) a
0.12 (´0.1, 0.34) c
´0.09 (´0.15, ´0.02)
´0.83 (´1.96, 0.3)
0.09 (´0.21, 0.39)
´0.14 (´0.44, 0.17)
—

0.70
0.28
0.01
0.15
0.57
0.38
—

p´value

β (95% CI)
d
c

0.12 (´1.91, 2.16)
0.21 (´0.01, 0.43)
´0.11 (´0.18, ´0.05)
´0.67 (´1.79, 0.45)
´0.11 (´0.41, 0.2)
´0.11 (´0.43, 0.2)
—

0.88
0.06
<0.01
0.24
0.49
0.48
—

3 Months (miss = 41)

6 Months (miss = 44)
p´value

β (95% CI)
b

0.11 (´2.58, 2.35)
0.21 (0.02, 0.40) c
´0.14 (´0.21,´0.07) d
´0.76 (–1.68, 0.17)
´0.04 (´0.29, 0.21)
´0.12 (´0.40, 0.16)
´0.11 (´0.22, ´0.01)

0.90
0.03
<0.01
0.12
0.76
0.39
0.04

p´value

β (95% CI)
d
c

0.12 (´1.44, 1.69)
0.12 (´0.11, 0.32)
´0.08 (´0.14, ´0.02)
´0.42 (–1.43, 0.59)
´0.27 (´0.55, 0.001)
´0.18 (´0.5, 0.13)
—

0.85
0.33
0.01
0.41
0.05
0.26
—

a

The effect of the intervention when baseline is 7. b The effect of the intervention when age is 65 and baseline is 7. c The effect of baseline intention in the intervention group.
The effect of age in the intervention group. e Linear interaction of Intervention and Baseline Intention effects (that is, the amount by which the Intervention effect changes for
each unit increase in Baseline Intention). f Linear interaction of Intervention and Age effects (that is, the amount by which the Intervention effect changes for each year increase
in Age).
d

Table 4. Estimated marginal mean changes in clinical trial intentions.
Mean Differences in Intention (95% CI) a
Assigned Group

Control
Intervention
a

Intention to Seek Information

Intention to Join

Baseline and 3
Months (miss = 42)

Baseline and 6
Months (miss = 43)

3 Months and 6
Months b (miss = 48)

Baseline and 3
Months (miss = 41)

Baseline and 6
Months (miss = 44)

3 Months and 6
Months (miss = 46)

1.08 (´0.44,2.6)
1.98 (0.47, 3.5) *

1.02 (´0.43, 2.47)
1.49 (0.05, 2.93) *

0.07 (´0.76, 0.9)
´0.29 (´1.11, 0.54)

0.09 (´1.15, 1.32)
0.36 (´0.86, 1.59)

´0.03 (´1.16, 1.1)
0.52 (´0.61, 1.65)

´0.18 (´1.54, 1.18)
0.22 (´1.14, 1.57)

All models adjust for baseline intention, age, and intervention * baseline intention.
was zero.

b

Used model without church random effect because estimated between-church variance
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Intention to join clinical trials at baseline was similar for the two groups as well, with the control
group having a mean baseline score of 5.8 out of 10 (SD = 2.7, missing = 4) and the intervention group
a score of 5.8 out of 10 (SD = 2.7, missing = 3) (Figure 1b). At 3 months, the mean score for the control
group was 5.9 out of 10 (SD = 2.7, missing = 4) and for the intervention group 6.2 out of 10 (SD = 2.8,
missing = 9). The mean intention score at 6 months was 5.7 out of 10 (SD = 3.0, missing = 5) for the
control group and 6.3 out of 10 (SD = 2.9, missing = 9) for the intervention group.
Results from the multivariable linear mixed models for three- and six-month intentions to seek
information about and join clinical trials are shown in Table 3. Participation in the intervention
group was not associated with greater improvement in intention to seek information about or join
clinical trials at follow-up. Age was significantly related to three-month intention to seek information
(p < 0.05), six-month intention to seek information (p < 0.01), three-month intention to join (p < 0.01),
and six-month intention to join (p < 0.05), with older participants indicating less increase, or greater
decrease, in intentions over baseline. There was a significant interaction between age and intervention
in the three-month model for intention to join clinical trials: in the intervention group, younger
age was significantly associated with more positive change in intention to join clinical trials at three
months relative to baseline (p < 0.01), while in the control group, age was not significantly associated
with a difference in the change in intention to join from baseline to three months (p = 0.51).
A summary of the estimated marginal mean change in the two trial participation intention
measures within each group resulting from the multivariable linear mixed models for mean changes
are presented in Table 4. In the intervention group, intention to seek information about clinical trials
on average increased significantly from baseline to three months (adjusted mean difference = 1.98,
p < 0.05) and from baseline to six months (adjusted mean difference = 1.49, p < 0.05), after adjustment
for baseline intentions, age, and interaction between baseline intentions and intervention. Control
group participants did not see a significant increase or decrease in intention to seek information about
clinical trials, on average, between any pair of time points. There were no significant changes in the
average intention to join between any pair of time points for either group.
4. Discussion
This study found that the comprehensive intervention “package” characteristics (i.e., church-based,
pastor-supported, based in social networks) likely resulted in the initiation of behavioral change
consistent with established theoretical models and persuasion frameworks [31–33].
Health
communication models indicate that persuasion occurs over a continuum and is bolstered by
repeated exposure to messages or content [34]. According to previous behavioral communication
studies, persuasion likely occurs at later time points after which the credibility of the source is
established through information verification processes also known as “assimilation” [35,36].
The results from this study demonstrate that the first step in motivating people to consider
participation—intention to seek information about clinical trials—increased significantly by three
months in the intervention group, much faster than we anticipated. Thus, with our participants
indicating that they were more likely to get information over this initial introductory program
period, the findings offered evidence that information seeking would precede behavioral initiation
accounting for the presence of “attitudinal ambivalence” [37]. This term refers to a condition
we expected would be present due to knowledge of medical abuses via oral history or, for the
intervention arm participants, stemming from our discussion of past clinical trials and ethics abuses
in medical and public health research. Our participants were likely to feel conflicted about the
information we would present, as their beliefs and knowledge would contribute to attitude formation
and subsequent participatory decisions to join or forego joining clinical trials. In other words, we
expected that we needed three sessions with our participants to establish our “source credibility”
and, consequently, to generate any motivation to attend to messages we presented about clinical
trials [36]. In reality, we needed only two sessions for participants to formulate their decision to seek
additional information and reduce attitudinal ambivalence.
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The study findings also indicate that intention to join clinical trials also seemed to increase by
the three-month time point, yet the increase was not statistically significant. Similarly, the effects
resulting from participation in the program diminished after three months. Both intention to seek
information about and intention to join clinical trials did not increase significantly between threeand six-month time points. Indeed, previous studies have demonstrated that persuasion is most
effective when study participants are exposed to strong messages, have time to think about them,
and have the ability to process the message in the face of counter-persuasion (e.g., negative enduring
beliefs and/or social norms about clinical trials) [34]. Our findings suggest that most processing likely
occurred in the first three months of program involvement and tapered off after that time point.
Although our participants indicated their intention to seek more information about clinical trials
at the three-month time point, there is insufficient evidence to attribute this observed, significant
increase to the intervention itself. It is possible that a portion of this increase is attributable to positive
interaction with the researchers, the perceived social influence of the church network involved with
the study, and the availability of information about current clinical trials that was provided to
both the control and intervention groups. As this program was developed in collaboration with
our Community Advisory Board, pastors from participating churches and their health ministers,
any effect may also be attributable in part to the Community-Based Participatory Research (CBPR)
processes that occurred [38]. Indeed, there is a growing body of literature on specific persuasive
effects that motivate older minorities to participate in research studies [39]. Specifically, hearing
the recommendations of family members, physicians, and others, combined with perceived social
support for participation, serve as powerful motivational queues [39]. Because control intentions also
appeared to increase slightly (though not statistically significantly), we believe all of the above likely
contributed to increased intentions; however, more experimental arms and additional research are
necessary to assess these effects.
The findings also correspond with those of previous studies that point to significant challenges
associated with the recruitment of elderly populations [10,19,26]. Advanced age (ě65 years) tempered
the increase in intentions over the course of the study; elderly participants in both groups displayed
smaller increases in intention (or greater decreases in intention) than their younger (50–64 years)
counterparts on both intention outcomes. This suggests that our participants were well-aware of their
personal limitations associated with participation, including reliance on others for transportation
to/from study visits, their physical immobility, and their health restrictions likely resulting in their
exclusion from studies. Thus, their intentions reflect an array of sociostructural and personal factors
that must be considered in future interventions seeking to enroll this group [40]. We argue that a
multi-pronged intervention which accounts for distance to/from clinical trial sites, transportation
options, and whose study promotion messages originate from the church would characterize a future
intervention model. In addition, it will be worth evaluating this time-intensive approach to other
strategies, such as direct patient outreach and mass advertising to determine its cost-benefit ratio.
We acknowledge the limitations in this study. The self-reported intentions to seek information
about or join clinical trials that are examined as the analytic outcomes are intermediate to the
behavioral outcomes of information seeking and joining clinical trials. However, these intermediate
outcomes provide important information about both the pathway to action for clinical trial
participation and the internal processes that may lead to action. We also recognize that this pilot
intervention is limited in its broader application based on these pilot results. Our interventions in
urban Atlanta churches may yield different results than those performed in other cities or in rural
areas, especially as the easy availability clinical trials relevant to the participants is necessary for
intervention success. On-site enrollment and trial implementation could help improve participation
where trial access is difficult [41]. We also know that the involvement of pastors and church leaders is
critical to recruitment and to congregant engagement in the intervention, yet their influence may also
introduce ethical concerns related to coercion. Our participating churches had a variety of educational
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backgrounds, and on average our participants had a relatively high degree of educational attainment,
making results difficult to generalize to churches serving congregants with less formal education.
5. Conclusions
After three months, participants from the intervention arm showed increased intentions to seek
information about clinical trials. These results suggest that the combination effect derived from
positive engagement with researchers, health ministers, pastors, and other subject matter experts in a
familiar faith-based setting, plus obtaining information about relevant clinical trials quickly, engages
older African Americans on research decision-making. Because these increased intentions were not
mirrored by participants of advanced age (ě65 years), it is likely that additional efforts must be made
to address the special barriers to research participation faced by the elderly. Nonetheless, this study
highlights the promise of church and faith networks as avenues through which to influence older
African Americans’ knowledge and attitudes towards clinical research participation.
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